A MASH Contender Puts Roche in the Spotlight

Roche’s move to acquire 89bio boosts a leading MASH therapy and opens new partnership opportunities across metabolic medicine

1 Dec 2025

Roche’s plan to buy 89bio, a deal that may reach $3.5bn, captures a moment of rising urgency in metabolic medicine. Announced in September, it comes as obesity, diabetes and advanced liver disease spread worldwide. The size of the bid suggests where the industry thinks the next wave of demand will fall.

The prize is pegozafermin, a candidate for treating MASH, a progressive liver disorder that affects millions of Americans. Early trials suggest it can cut liver fat and inflammation, signals of a drug that could gain ground in a market preparing for rapid expansion. For Roche, the purchase offers a chance to broaden its portfolio just as interest in complex metabolic therapies reaches a peak.

Analysts see a broader pivot. Weight loss drugs have dominated attention, yet firms are now chasing medicines that repair metabolic damage rather than merely lower weight. Pegozafermin’s biology has drawn notice because it may work alongside today’s buzzy treatments. One analyst argued that metabolic care is entering an era that will "rely on multiple coordinated treatments" and that Roche’s move marks the start.

Regulators, however, are still shaping rules for MASH therapies and rivals are pushing forward their own candidates. Health systems may also be slower to adopt these medicines than they were with slimming drugs. Even so, expectations remain high. Roche’s global reach could speed development and bring the drug to patients sooner.

The signal is unmistakable. As metabolic illness grows, companies are funnelling capital into therapies that may reshape care over the next decade. If pegozafermin fulfils its early promise, this deal may be remembered as the moment metabolic medicine turned a corner.